TVM Capital Life Science

TVM Capital Life Science employs a dual-pronged investment strategy focused on life science innovation. The first prong involves financing innovative early-stage therapeutics through single-asset companies, leveraging their strategic relationship with Eli Lilly and Company. This approach aims to de-risk early-stage assets by bringing them to clinical proof-of-concept. The second prong involves investing in differentiated commercial-stage medtech, diagnostics, and digital health products, as well as late-stage therapeutics. This focuses on companies with products that have the potential to transform medical practice and achieve a clear and attractive exit strategy. The firm's mission is to invest in the development of exciting life science products and the growth of companies to become innovative leaders in their market segment. They strive to be true partners, working closely with their portfolio companies to enable their ideas and bring new therapies and medical products to market. TVM contributes more than just capital, providing portfolio companies with support including recruiting new management and board members, honing development, sales and marketing plans, QMS and manufacturing/supply chain logistics, regulatory strategies, finding potential partners and carrying out financing and exit strategies. TVM focuses on investing in assets and companies that provide a clear and attractive exit strategy from the outset, with the goal of maximizing returns in a reasonable timeframe. This includes de-risked biopharma and medical device products. They look for companies that can reach value inflection points at the next stage of development or growth where they can have several solid exit options. TVM strategically refocused in 2012 to best exploit untapped industry potential. TVM Capital Life Science was born out of venture capital firm Techno Venture Management, which was launched in 1983 and has focused exclusively on Life Sciences since 2012. TVM Capital Life Science has emerged as one of the leading international venture capital firms in the field.